Pharmacotherapy of insomnia

Bibliography

• Roth T, Coulouvrat C, Hajak G, Prevalence and perceived health associated with insomnia based on DSM-IV-TR; International Statistical Classification of Diseases and Related Health Problems, Tenth Revision; and Research Diagnostic Criteria/International Classification of Sleep Disorders, Second Edition criteria: results from the America Insomnia Survey. Biol Psychiatry 2011;69:592-600
   PubMed Web of Science ®Google Scholar
• Sarsour K, Kalsekar A, Swindle R, The association between insomnia severity and healthcare and productivity costs in a health plan sample. Sleep 2011;34:443-50
   PubMed Web of Science ®Google Scholar
• Ohayon MM. Epidemiology of insomnia: what we know and what we still need to learn. Sleep Medicine Reviews 2002;6:97-111
   PubMed Web of Science ®Google Scholar
• Hohagen F, Kappler C, Schramm E, Sleep onset insomnia, sleep maintaining insomnia and insomnia with early morning awakening–temporal stability of subtypes in a longitudinal study on general practice attenders. Sleep 1994;17:551-4
   PubMed Web of Science ®Google Scholar
• Roth T, Drake C. Defining insomnia: the role of quantitative criteria. Sleep 2006;29:424-5
   PubMed Web of Science ®Google Scholar
• Roth T, Jaeger S, Jin R, Sleep problems, comorbid mental disorders, and role functioning in the national comorbidity survey replication. Biological Psychiatry 2006;60:1364-71
   PubMed Web of Science ®Google Scholar
• Jansson-Frojmark M, Lindblom K. A bidirectional relationship between anxiety and depression, and insomnia? A prospective study in the general population. Journal of Psychosomatic Research 2008;64:443-9
   PubMed Web of Science ®Google Scholar
• Morin CM, Belanger L, LeBlanc M, The natural history of insomnia: a population-based 3-year longitudinal study. Arch Intern Med 2009;169:447-53
   PubMed Web of Science ®Google Scholar
• Roth T. Insomnia: definition, prevalence, etiology, and consequences. J Clin Sleep Med 2007;3:S7-10
   PubMed Web of Science ®Google Scholar
• Ohayon MM, Caulet M, Guilleminault C. How a general population perceives its sleep and how this relates to the complaint of insomnia. Sleep 1997;20:715-23
   PubMed Web of Science ®Google Scholar
• Ohayon MM, Caulet M, Priest RG, Guilleminault C. DSM-IV and ICSD-9 - insomnia symptoms and sleep dissatisfaction. Br J Psychiatry 1997;171:382-8
   PubMed Web of Science ®Google Scholar
• Li RH, Wing YK, Ho SC, Fong SY. Gender differences in insomnia–a study in the Hong Kong Chinese population. J Psychosom Res 2002;53:601-9
   PubMed Web of Science ®Google Scholar
• Stone KC, Taylor DJ, McCrae CS, Nonrestorative sleep. Sleep Med Rev 2008;12:275-88
   PubMed Web of Science ®Google Scholar
• Taylor DJ. Insomnia and depression. Sleep 2008;31:447-8
   PubMed Web of Science ®Google Scholar
• Buysse DJ, Angst J, Gamma A, Prevalence, course, and comorbidity of insomnia and depression in young adults. Sleep 2008;31:473-80
   PubMed Web of Science ®Google Scholar
• Pigeon WR, Hegel M, Unutzer J, Is insomnia a perpetuating factor for late-life depression in the IMPACT cohort? Sleep 2008;31:481-8
   PubMed Web of Science ®Google Scholar
• Liu X. Sleep and adolescent suicidal behavior. Sleep 2004;27:1351-8
   PubMed Web of Science ®Google Scholar
• Baglioni C, Battagliese G, Feige B, Insomnia as a predictor of depression: a meta-analytic evaluation of longitudinal epidemiological studies. Journal of Affective Disorders 2011;135:10-19
   PubMed Web of Science ®Google Scholar
• Available from: http://www.sleepfoundation.org/sites/default/files/sleepinamericapoll/SIAP_2011_Summary_of_Findings.pdf [Accessed January 2012] 2011
   Google Scholar
• Balter MB, Uhlenhuth EH. The beneficial and adverse effects of hypnotics. J Clin Psychiatry 1991;52(Suppl):16-23
   PubMed Web of Science ®Google Scholar
• Roth T, Ancoli-Israel S. Daytime consequences and correlates of insomnia in the United States: results of the 1991 National Sleep Foundation Survey. II. Sleep 1999;22(Suppl 2):S354-8
   PubMed Web of Science ®Google Scholar
• Kuppermann M, Lubeck DP, Mazonson PD, Sleep problems and their correlates in a working population. J Gen Intern Med 1995;10:25-32
   PubMed Web of Science ®Google Scholar
• Ozminkowski RJ, Wang S, Walsh JK. The direct and indirect costs of untreated insomnia in adults in the United States. Sleep 2007;30:263-73
   PubMed Web of Science ®Google Scholar
• Walsh JK, Engelhardt CL. The direct economic costs of insomnia in the United States for 1995. Sleep 1999;22(Suppl 2):S386-93
   PubMed Web of Science ®Google Scholar
• Katz DA, McHorney CA. The relationship between insomnia and health-related quality of life in patients with chronic illness. J Fam Pract 2002;51:229-35
   PubMed Web of Science ®Google Scholar
• American Psychiatry Association. DSM-5 development Sleep-wake disorders. Available from: http://www.dsm5.org/proposedrevision/pages/sleep-wakedisorders.aspx [Last accessed January 2012] 2010
   Google Scholar
• Bonnet MH. Hyperarousal and insomnia. Sleep Med Rev 2010;14:33
   PubMed Web of Science ®Google Scholar
• Bhat A, Shafi F, El Solh AA. Pharmacotherapy of insomnia. Expert Opin Pharmacother 2008;9:351-62
   PubMed Web of Science ®Google Scholar
• Montgomery P, Dennis J. A systematic review of non-pharmacological therapies for sleep problems in later life. Sleep Med Rev 2004;8:47-62
   PubMed Web of Science ®Google Scholar
• Smith MT, Perlis ML, Park A, Comparative meta-analysis of pharmacotherapy and behavior therapy for persistent insomnia. Am J Psychiatry 2002;159:5-11
   PubMed Web of Science ®Google Scholar
• Morin CM, Colecchi C, Stone J, Behavioral and pharmacological therapies for late-life insomnia: a randomized controlled trial. JAMA 1999;281:991-9
   PubMed Web of Science ®Google Scholar
• Morin CM, Bootzin RR, Buysse DJ, Psychological and behavioral treatment of insomnia: update of the recent evidence (1998 – 2004). Sleep 2006;29:1398-414
   PubMed Web of Science ®Google Scholar
• Stepanski EJ, Wyatt JK. Use of sleep hygiene in the treatment of insomnia. Sleep Med Rev 2003;7:215-25
   PubMed Web of Science ®Google Scholar
• Health NIo. National Institutes of Health state of the science conference statement on manifestations and management of chronic insomnia in adults. Sleep 2005;28:59
   Web of Science ®Google Scholar
• Schutte-Rodin S, Broch L, Buysse D, Clinical guideline for the evaluation and management of chronic insomnia in adults. J Clin Sleep Med 2008;4:487-504
   PubMed Web of Science ®Google Scholar
• Mohler H, Fritschy JM, Rudolph U. A new benzodiazepine pharmacology. J Pharmacol Exp Ther 2002;300:2-8
   PubMed Web of Science ®Google Scholar
• Zhang D, Pan ZH, Awobuluyi M, Lipton SA. Structure and function of GABA(C) receptors: a comparison of native versus recombinant receptors. Trends Pharmacol Sci 2001;22:121-32
   PubMed Web of Science ®Google Scholar
• Olsen RW, Sieghart W. International union of pharmacology. LXX. Subtypes of gamma-aminobutyric acid(A) receptors: classification on the basis of subunit composition, pharmacology, and function. Update. Pharmacol Rev 2008;60:243-60
   PubMed Web of Science ®Google Scholar
• Burt DR. Reducing GABA receptors. Life Sci 2003;73:1741-58
   PubMed Web of Science ®Google Scholar
• Smith AJ, Alder L, Silk J, Effect of alpha subunit on allosteric modulation of ion channel function in stably expressed human recombinant gamma-aminobutyric acid(A) receptors determined using (36)Cl ion flux. Mol Pharmacol 2001;59:1108-18
   PubMed Web of Science ®Google Scholar
• Rudolph U, Crestani F, Benke D, Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes. Nature 1999;401:796-800
   PubMed Web of Science ®Google Scholar
• Rudolph U, Mohler H. Analysis of GABAA receptor function and dissection of the pharmacology of benzodiazepines and general anesthetics through mouse genetics. Annu Rev Pharmacol Toxicol 2004;44:475-98
   PubMed Web of Science ®Google Scholar
• Bowery NG. GABAB receptor pharmacology. Annu Rev Pharmacol Toxicol 1993;33:109-47
   PubMed Web of Science ®Google Scholar
• Couve A, Moss SJ, Pangalos MN. GABAB receptors: a new paradigm in G protein signaling. Mol Cell Neurosci 2000;16:296-312
   PubMed Web of Science ®Google Scholar
• Ng GY, Clark J, Coulombe N, Identification of a GABAB receptor subunit, gb2, required for functional GABAB receptor activity. J Biol Chem 1999;274:7607-10
   PubMed Web of Science ®Google Scholar
• Shimada S, Cutting G, Uhl GR. gamma-Aminobutyric acid A or C receptor? gamma-Aminobutyric acid rho 1 receptor RNA induces bicuculline-, barbiturate-, and benzodiazepine-insensitive gamma-aminobutyric acid responses in Xenopus oocytes. Mol Pharmacol 1992;41:683-7
   PubMed Web of Science ®Google Scholar
• Nowell PD, Mazumdar S, Buysse DJ, Benzodiazepines and zolpidem for chronic insomnia: a meta-analysis of treatment efficacy. JAMA 1997;278:2170-7
   PubMed Web of Science ®Google Scholar
• Holbrook AM, Crowther R, Lotter A, Meta-analysis of benzodiazepine use in the treatment of insomnia. CMAJ 2000;162:225-33
   PubMed Web of Science ®Google Scholar
• Roth T, Roehrs TA. A review of the safety profiles of benzodiazepine hypnotics. J Clin Psychiatry 1991;52(Suppl):38-41
   PubMedGoogle Scholar
• Mendelson W. Clinical distinctions between long-acting and short-acting benzodiazepines. J Clin Psychiatry 1992;53(Suppl):2
   Google Scholar
• Roehrs T, Merlotti L, Zorick F, Roth T. Rebound insomnia in normals and patients with insomnia after abrupt and tapered discontinuation. Psychopharmacology 1992;108:67-71
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, Harmatz JS, Zinny MA, Shader RI. Effect of gradual withdrawal on the rebound sleep disorder after discontinuation of triazolam. N Engl J Med 1987;317:722-8
   PubMed Web of Science ®Google Scholar
• Roehrs T, Pedrosi B, Rosenthal L, Roth T. Hypnotic self administration and dose escalation. Psychopharmacology 1996;127:150-4
   PubMed Web of Science ®Google Scholar
• Paterniti S, Dufouil C, Alperovitch A. Long-term benzodiazepine use and cognitive decline in the elderly: the Epidemiology of Vascular Aging Study. J Clin Psychopharmacol 2002;22:285-93
   PubMed Web of Science ®Google Scholar
• Avidan AY, Fries BE, James ML, Insomnia and hypnotic use, recorded in the minimum data set, as predictors of falls and hip fractures in michigan nursing homes. J Am Geriatr Soc 2005;53:955-62
   PubMed Web of Science ®Google Scholar
• Kelly KD, Pickett W, Yiannakoulias N, Medication use and falls in community-dwelling older persons. Age Ageing 2003;32:503-9
   PubMed Web of Science ®Google Scholar
• Ray WA, Griffin MR, Downey W. Benzodiazepines of long and short elimination half-life and the risk of hip fracture. JAMA 1989;262:3303-7
   PubMed Web of Science ®Google Scholar
• Ambien [package insert]. Sanofi-Synthelabo, Inc.; New York, NY: 2004
   Google Scholar
• Pressman MR, Mahowald MW, Schenck CH. Sleep terrors/sleepwalking–not REM behavior disorder. Sleep 2005;28:278-9
   PubMed Web of Science ®Google Scholar
• Micromedex 2.0. Available from: http://www.thomsonhc.com/micromedex2/librarian [Last accessed January 2012] 2012
   Google Scholar
• Greenblatt DJ, Legangneux E, Harmatz JS, Dynamics and kinetics of a modified-release formulation of zolpidem: comparison with immediate-release standard zolpidem and placebo. J Clin Pharmacol 2006;46:1469-80
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, von Moltke LL, Harmatz JS, Differential impairment of triazolam and zolpidem clearance by ritonavir. J Acquir Immune Defic Syndr 2000;24:129-36
   PubMed Web of Science ®Google Scholar
• Scharf MB, Roth T, Vogel GW, Walsh JK. A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia. J Clin Psychiatry 1994;55:192-9
   PubMed Web of Science ®Google Scholar
• Roehrs TA, Randall S, Harris E, Twelve months of nightly zolpidem does not lead to dose escalation: a prospective placebo-controlled study. Sleep 2011;34:207-12
   PubMed Web of Science ®Google Scholar
• Krystal AD, Erman M, Zammit GK, Long-term efficacy and safety of zolpidem extended-release 12.5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: a 6-month, randomized, double-blind, placebo-controlled, parallel-group, multicenter study. Sleep 2008;31:79-90
   PubMed Web of Science ®Google Scholar
• Erman M, Guiraud A, Joish VN, Lerner D. Zolpidem extended-release 12.5 mg associated with improvements in work performance in a 6-month randomized, placebo-controlled trial. Sleep 2008;31:1371-8
   PubMed Web of Science ®Google Scholar
• Zolpimist [package insert]. ECR Pharmaceuticals; Richmond, VA: 2010
   Google Scholar
• Intermezzo [package insert]. Transcept Pharmaceuticals, Inc.; Pt. Richmond, CA: 2011
   Google Scholar
• Holm KJ, Goa KL. Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia. Drugs 2000;59:865-89
   PubMed Web of Science ®Google Scholar
• Elie R, Ruther E, Farr I, Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic. Zaleplon Clinical Study Group. J Clin Psychiatry 1999;60:536-44
   PubMed Web of Science ®Google Scholar
• Mendelson WB. Sleepwalking associated with zolpidem. J Clin Psychopharmacol 1994;14:150
   PubMed Web of Science ®Google Scholar
• Canaday BR. Amnesia possibly associated with zolpidem administration. Pharmacotherapy 1996;16:687-9
   PubMed Web of Science ®Google Scholar
• Sattar SP, Ramaswamy S, Bhatia SC, Petty F. Somnambulism due to probable interaction of valproic acid and zolpidem. Ann Pharmacother 2003;37:1429-33
   PubMed Web of Science ®Google Scholar
• Morgenthaler TI, Silber MH. Amnestic sleep-related eating disorder associated with zolpidem. Sleep Med 2002;3:323-7
   PubMedGoogle Scholar
• Lange CL. Medication-associated somnambulism. J Am Acad Child Adolesc Psychiatry 2005;44:211-12
   PubMed Web of Science ®Google Scholar
• Yang W, Dollear M, Muthukrishnan SR. One rare side effect of zolpidem–sleepwalking: a case report. Arch Phys Med Rehabil 2005;86:1265-6
   PubMed Web of Science ®Google Scholar
• Staner L, Eriksson M, Cornette F, Sublingual zolpidem is more effective than oral zolpidem in initiating early onset of sleep in the post-nap model of transient insomnia: a polysomnographic study. Sleep Med 2009;10:616-20
   PubMed Web of Science ®Google Scholar
• Staner C, Joly F, Jacquot N, Sublingual zolpidem in early onset of sleep compared to oral zolpidem: polysomnographic study in patients with primary insomnia. Curr Med Res Opin 2010;26:1423-31
   PubMed Web of Science ®Google Scholar
• Roth T, Hull SG, Lankford DA, Low-dose sublingual zolpidem tartrate is associated with dose-related improvement in sleep onset and duration in insomnia characterized by middle-of-the-night (MOTN) awakenings. Sleep 2008;31:1277-84
   PubMed Web of Science ®Google Scholar
• Sonata [package insert]. Wyeth; Philadelphia, PA: 2004
   Google Scholar
• Damgen K, Luddens H. Zaleplon displays selectivity to recombinant GABA-A receptors different from zolpidem, zopiclone and benzodiazepines. Neurosci Res Commun 1999;25:10
   Google Scholar
• Sanna E, Busonero F, Talani G, Comparison of the effects of zaleplon, zolpidem, and triazolam at various GABA(A) receptor subtypes. Eur J Pharmacol 2002;451:103-10
   PubMed Web of Science ®Google Scholar
• Walsh JK, Pollak CP, Scharf MB, Lack of residual sedation following middle-of-the-night zaleplon administration in sleep maintenance insomnia. Clin Neuropharmacol 2000;23:17-21
   PubMed Web of Science ®Google Scholar
• Zammit GK, Corser B, Doghramji K, Sleep and residual sedation after administration of zaleplon, zolpidem, and placebo during experimental middle-of-the-night awakening. J Clin Sleep Med 2006;2:417-23
   PubMed Web of Science ®Google Scholar
• Huang YS, Hsu SC, Liu SI, Chen CK. A double-blind, randomized, comparative study to evaluate the efficacy and safety of zaleplon versus zolpidem in shortening sleep latency in primary insomnia. Chang Gung Med J 2011;34:50-6
   PubMedGoogle Scholar
• Ancoli-Israel S, Walsh JK, Mangano RM, Fujimori M. Zaleplon, a novel nonbenzodiazepine hypnotic, effectively treats insomnia in elderly patients without causing rebound effects. Prim Care Companion J Clin Psychiatry 1999;1:114-20
   PubMedGoogle Scholar
• Ware JC, Walsh JK, Scharf MB, Minimal rebound insomnia after treatment with 10-mg zolpidem. Clin Neuropharmacol 1997;20:116-25
   PubMed Web of Science ®Google Scholar
• Roehrs TA, Randall S, Harris E, Twelve months of nightly zolpidem does not lead to rebound insomnia or withdrawal symptoms: a prospective placebo-controlled study. J Psychopharmacol 2011. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Lunesta [package insert]. Sepracor; Marlborough, MA: 2005
   Google Scholar
• Krystal AD, Walsh JK, Laska E, Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep 2003;26:793-9
   PubMed Web of Science ®Google Scholar
• Zammit GK, McNabb LJ, Caron J, Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia. Curr Med Res Opin 2004;20:1979-91
   PubMed Web of Science ®Google Scholar
• Walsh JK, Krystal AD, Amato DA, Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep 2007;30:959-68
   PubMed Web of Science ®Google Scholar
• Scharf M, Erman M, Rosenberg R, A 2-week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep 2005;28:720-7
   PubMed Web of Science ®Google Scholar
• McCall WV, Erman M, Krystal AD, A polysomnography study of eszopiclone in elderly patients with insomnia. Curr Med Res Opin 2006;22:1633-42
   PubMed Web of Science ®Google Scholar
• Soares CN, Joffe H, Rubens R, Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomized controlled trial. Obstet Gynecol 2006;108:1402-10
   PubMed Web of Science ®Google Scholar
• Fava M, McCall WV, Krystal A, Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biol Psychiatry 2006;59:1052-60
   PubMed Web of Science ®Google Scholar
• Pollack M, Kinrys G, Krystal A, Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Arch Gen Psychiatry 2008;65:551-62
   PubMed Web of Science ®Google Scholar
• Joffe H, Petrillo L, Viguera A, Eszopiclone improves insomnia and depressive and anxious symptoms in perimenopausal and postmenopausal women with hot flashes: a randomized, double-blinded, placebo-controlled crossover trial. Am J Obstet Gynecol 2010;202:171; e171-171 e111
   PubMed Web of Science ®Google Scholar
• Fava M, Asnis GM, Shrivastava RK, Improved insomnia symptoms and sleep-related next-day functioning in patients with comorbid major depressive disorder and insomnia following concomitant zolpidem extended-release 12.5 mg and escitalopram treatment: a randomized controlled trial. J Clin Psychiatry 2011;72:914-28
   PubMed Web of Science ®Google Scholar
• Pollack MH, Hoge EA, Worthington JJ, Eszopiclone for the treatment of posttraumatic stress disorder and associated insomnia: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2011;72:892-7
   PubMed Web of Science ®Google Scholar
• Fava M, Schaefer K, Huang H, A post hoc analysis of the effect of nightly administration of eszopiclone and a selective serotonin reuptake inhibitor in patients with insomnia and anxious depression. J Clin Psychiatry 2011;72:473-9
   PubMed Web of Science ®Google Scholar
• Roth T, Walsh JK, Krystal A, An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia. Sleep Med 2005;6:487-95
   PubMed Web of Science ®Google Scholar
• Wikner BN, Kallen B. Are hypnotic benzodiazepine receptor agonists teratogenic in humans? J Clin Psychopharmacol 2011;31:356-9
   PubMed Web of Science ®Google Scholar
• Krystal AD. A compendium of placebo-controlled trials of the risks/benefits of pharmacological treatments for insomnia: the empirical basis for U.S. clinical practice. Sleep Med Rev 2009;13:265-74
   PubMed Web of Science ®Google Scholar
• Hirai K, Kita M, Ohta H, Ramelteon (TAK-375) accelerates reentrainment of circadian rhythm after a phase advance of the light-dark cycle in rats. J Biol Rhythms 2005;20:27-37
   PubMed Web of Science ®Google Scholar
• Miyamoto M, Nishikawa H, Doken Y, The sleep-promoting action of ramelteon (TAK-375) in freely moving cats. Sleep 2004;27:1319-25
   PubMed Web of Science ®Google Scholar
• Hughes RJ, Sack RL, Lewy AJ. The role of melatonin and circadian phase in age-related sleep-maintenance insomnia: assessment in a clinical trial of melatonin replacement. Sleep 1998;21:52-68
   PubMed Web of Science ®Google Scholar
• Haimov I, Lavie P, Laudon M, Melatonin replacement therapy of elderly insomniacs. Sleep 1995;18:598-603
   PubMed Web of Science ®Google Scholar
• MacFarlane JG, Cleghorn JM, Brown GM, Streiner DL. The effects of exogenous melatonin on the total sleep time and daytime alertness of chronic insomniacs: a preliminary study. Biol Psychiatry 1991;30:371-6
   PubMed Web of Science ®Google Scholar
• Montes LGA, Ontiveros Uribe MP, Cortes Sotres J. Treatment of primary insomnia with melatonin: a double-blind, placebo-controlled, cross-over study. J Psychiatry Neurosci 2003;28:6
   Web of Science ®Google Scholar
• Brzezinski A, Vangel MG, Wurtman RJ, Effects of exogenous melatonin on sleep: a meta-analysis. Sleep Med Rev 2005;9:41-50
   PubMed Web of Science ®Google Scholar
• Leger D, Laudon M, Zisapel N. Nocturnal 6-sulfatoxymelatonin excretion in insomnia and its relation to the response to melatonin replacement therapy. Am J Med 2004;116:91-5
   PubMed Web of Science ®Google Scholar
• Haimov I, Laudon M, Zisapel N, Sleep disorders and melatonin rhythms in elderly people. BMJ 1994;309:167
   PubMed Web of Science ®Google Scholar
• Sack RL, Brandes RW, Kendall AR, Lewy AJ. Entrainment of free-running circadian rhythms by melatonin in blind people. N Engl J Med 2000;343:1070-7
   PubMed Web of Science ®Google Scholar
• Hardeland R. New approaches in the management of insomnia: weighing the advantages of prolonged-release melatonin and synthetic melatoninergic agonists. Neuropsychiatr Dis Treat 2009;5:341-54
   PubMed Web of Science ®Google Scholar
• Rondanelli M, Opizzi A, Monteferrario F, The effect of melatonin, magnesium, and zinc on primary insomnia in long-term care facility residents in Italy: a double-blind, placebo-controlled clinical trial. J Am Geriatr Soc 2011;59:82-90
   PubMed Web of Science ®Google Scholar
• Rozerem [package insert]. Takeda Laboratories; Lincolnshire, Ill: 2005
   Google Scholar
• Ekmekcioglu C. Melatonin receptors in humans: biological role and clinical relevance. Biomed Pharmacother 2006;60:97-108
   PubMed Web of Science ®Google Scholar
• Stevenson S, Cornelissen K, Clarke E. Study of the absorbtion, metabolism and excretion of ramelteon (TAK-375) [abstract]. Clin Pharmacol Ther 2004;75:1
   PubMed Web of Science ®Google Scholar
• Tolbert DK, Karim A, Zhao Z. Evaluation of the single and multiple doses pharmacokinetics of ramelteon (TAK-375) in subjects with and without renal impairment [abstract]. J Clin Pharmacol 2004;44:1
   Web of Science ®Google Scholar
• Sainati SMK, A, Tolbert D. Effects of multiple doses of fluoxetine on the systemic exposure of a single dose of ramelteon (TAK-375) in healthy adults [abstract]. Sleep 2004;27
   Web of Science ®Google Scholar
• Karim AT, Tolbert D, Cao C. Effects of fluconazole and ketoconazole on the pharmacokinetics of ramelteon (TAK-376) in normal healthy male and female subjects [abstract]. Sleep 2004;27:2
   Web of Science ®Google Scholar
• Roth T, Stubbs C, Walsh JK. Ramelteon (TAK-375), a selective MT1/MT2-receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment. Sleep 2005;28:303-7
   PubMed Web of Science ®Google Scholar
• Erman M, Seiden D, Zammit G, An efficacy, safety, and dose-response study of Ramelteon in patients with chronic primary insomnia. Sleep Med 2006;7:17-24
   PubMed Web of Science ®Google Scholar
• Zammit GR, Roth T, Erman M. Double-blind placebo-controlled polysomnography and outpatient trial to evaluate the efficacy of ramelteon in adult patients with chronic insomnia [abstract]. Sleep 2006;28:1
   Web of Science ®Google Scholar
• Roth T, Seiden D, Sainati S, Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia. Sleep Med 2006;7:312-18
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, Harmatz JS, Karim A. Age and gender effects on the pharmacokinetics and pharmacodynamics of ramelteon, a hypnotic agent acting via melatonin receptors MT1 and MT2. J Clin Pharmacol 2007;47:485-96
   PubMed Web of Science ®Google Scholar
• Stubbs C, Karim A. A safety, tolerance and pharmacokinetic study of five single doses of TAK-375 in healthy adults. Sleep 2003;26:1
   Web of Science ®Google Scholar
• Johnson MW, Suess PE, Griffiths RR. Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects. Arch Gen Psychiatry 2006;63:1149-57
   PubMed Web of Science ®Google Scholar
• McGechan A, Wellington K. Ramelteon. CNS Drugs 2005;19:1057-65; discussion 1066-1057
   PubMed Web of Science ®Google Scholar
• Kato K, Hirai K, Nishiyama K, Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology 2005;48:301-10
   PubMed Web of Science ®Google Scholar
• Ferguson SA, Rajaratnam SM, Dawson D. Melatonin agonists and insomnia. Expert Rev Neurother 2010;10:305-18
   PubMed Web of Science ®Google Scholar
• Arendt J, Rajaratnam SM. Melatonin and its agonists: an update. Br J Psychiatry 2008;193:267-9
   PubMed Web of Science ®Google Scholar
• Rajaratnam SM, Polymeropoulos MH, Fisher DM, Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials. Lancet 2009;373:482-91
   PubMed Web of Science ®Google Scholar
• Hardeland R. Tasimelteon, a melatonin agonist for the treatment of insomnia and circadian rhythm sleep disorders. Curr Opin Investig Drugs 2009;10:691-701
   PubMed Web of Science ®Google Scholar
• Demyttenaere K. Agomelatine: a narrative review. Eur Neuropsychopharmacol 2011;21(Suppl 4):S703-9
   PubMed Web of Science ®Google Scholar
• Descamps A, Rousset C, Millan MJ, Influence of the novel antidepressant and melatonin agonist/serotonin2C receptor antagonist, agomelatine, on the rat sleep-wake cycle architecture. Psychopharmacology 2009;205:93-106
   PubMed Web of Science ®Google Scholar
• Leproult R, Van Onderbergen A, L'Hermite-Baleriaux M, Phase-shifts of 24-h rhythms of hormonal release and body temperature following early evening administration of the melatonin agonist agomelatine in healthy older men. Clin Endocrinol 2005;63:298-304
   PubMed Web of Science ®Google Scholar
• Walsh JK. Drugs used to treat insomnia in 2002: regulatory-based rather than evidence-based medicine. Sleep 2004;27:1441-2
   PubMed Web of Science ®Google Scholar
• Mendelson WB. A review of the evidence for the efficacy and safety of trazodone in insomnia. J Clin Psychiatry 2005;66:469-76
   PubMed Web of Science ®Google Scholar
• Walsh JKE, Erman M, Erwin CW. Subjective hypnotic efficacy of trazodone and zolpidem in DSM-III-R primary insomnia. Hum Psychopharmacol 1998;13:8
   Web of Science ®Google Scholar
• Yamadera H, Nakamura S, Suzuki H, Endo S. Effects of trazodone hydrochloride and imipramine on polysomnography in healthy subjects. Psychiatry Clin Neurosci 1998;52:439-43
   PubMed Web of Science ®Google Scholar
• Montgomery I, Oswald I, Morgan K, Adam K. Trazodone enhances sleep in subjective quality but not in objective duration. Br J Clin Pharmacol 1983;16:139-44
   PubMed Web of Science ®Google Scholar
• Carson CC III, Mino RD. Priapism associated with trazodone therapy. The Journal of Urology 1988;139:369-70
   PubMed Web of Science ®Google Scholar
• Compton-Mcbride SS, Schweitzer PK, Walsh JK. Most commonly used drugs to treat insomnia in 2002. Sleep 2004;27(Suppl):1
   Google Scholar
• Riemann D, Voderholzer U, Cohrs S, Trimipramine in primary insomnia: results of a polysomnographic double-blind controlled study. Pharmacopsychiatry 2002;35:165-74
   PubMed Web of Science ®Google Scholar
• Hohagen F, Montero RF, Weiss E, Treatment of primary insomnia with trimipramine: an alternative to benzodiazepine hypnotics? Eur Arch Psychiatry Clin Neurosci 1994;244:65-72
   PubMed Web of Science ®Google Scholar
• Winokur A, DeMartinis NA III, McNally DP, Comparative effects of mirtazapine and fluoxetine on sleep physiology measures in patients with major depression and insomnia. J Clin Psychiatry 2003;64:1224-9
   PubMed Web of Science ®Google Scholar
• Schittecatte M, Dumont F, Machowski R, Effects of mirtazapine on sleep polygraphic variables in major depression. Neuropsychobiology 2002;46:197-201
   PubMed Web of Science ®Google Scholar
• Winokur A, Sateia MJ, Hayes JB, Acute effects of mirtazapine on sleep continuity and sleep architecture in depressed patients: a pilot study. Biol Psychiatry 2000;48:75-8
   PubMed Web of Science ®Google Scholar
• Sorensen M, Jorgensen J, Viby-Mogensen J, A double-blind group comparative study using the new anti-depressant Org 3770, placebo and diazepam in patients with expected insomnia and anxiety before elective gynaecological surgery. Acta Psychiatr Scand 1985;71:339-46
   PubMed Web of Science ®Google Scholar
• Rodenbeck A, Cohrs S, Jordan W, The sleep-improving effects of doxepin are paralleled by a normalized plasma cortisol secretion in primary insomnia. A placebo-controlled, double-blind, randomized, cross-over study followed by an open treatment over 3 weeks. Psychopharmacology (Berl) 2003;170:423-8
   PubMed Web of Science ®Google Scholar
• Hajak G, Rodenbeck A, Adler L, Nocturnal melatonin secretion and sleep after doxepin administration in chronic primary insomnia. Pharmacopsychiatry 1996;29:187-92
   PubMed Web of Science ®Google Scholar
• Hajak G, Rodenbeck A, Voderholzer U, Doxepin in the treatment of primary insomnia: a placebo-controlled, double-blind, polysomnographic study. J Clin Psychiatry 2001;62:453-63
   PubMed Web of Science ®Google Scholar
• Hsu TR, Rogowski R, Roth T. Low-dose doxepin in the treatment of primary insomnia [abstract 0150]. Program and abstracts of the Asociated Professional Sleep Societies, 19th annual meeting; 18 – 23 June 2005; Denver, Colorado
   Google Scholar
• Krystal AD, Durrence HH, Scharf M, Efficacy and safety of doxepin 1 mg and 3 mg in a 12-week sleep laboratory and outpatient trial of elderly subjects with chronic primary insomnia. Sleep 2010;33:1553-61
   PubMed Web of Science ®Google Scholar
• Salin-Pascual RJ, Herrera-Estrella M, Galicia Polo L. Olanzapine acute administration in schizophrenic patients increases delta sleep and sleep efficiency. Biol Psychiatry 1999;46:3
   Web of Science ®Google Scholar
• Walsh JK, Perlis M, Rosenthal M, Tiagabine increases slow-wave sleep in a dose-dependent fashion without affecting traditional efficacy measures in adults with primary insomnia. J Clin Sleep Med 2006;2:35-41
   PubMed Web of Science ®Google Scholar
• Roth T, Wright KP Jr, Walsh J. Effect of tiagabine on sleep in elderly subjects with primary insomnia: a randomized, double-blind, placebo-controlled study. Sleep 2006;29:335-41
   PubMed Web of Science ®Google Scholar
• Deacon S, Staner L, Staner C, Effect of short-term treatment with gaboxadol on sleep maintenance and initiation in patients with primary insomnia. Sleep 2007;30:281-7
   PubMed Web of Science ®Google Scholar
• Lundahl J, Staner L, Staner C, Short-term treatment with gaboxadol improves sleep maintenance and enhances slow wave sleep in adult patients with primary insomnia. Psychopharmacology (Berl) 2007;195:139-46
   PubMed Web of Science ®Google Scholar
• Herrick-Davis K, Grinde E, Teitler M. Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors. J Pharmacol Exp Ther 2000;295:226-32
   PubMed Web of Science ®Google Scholar
• Yadav PN, Kroeze WK, Farrell MS, Roth BL. Antagonist functional selectivity: 5-HT2A serotonin receptor antagonists differentially regulate 5-HT2A receptor protein level in vivo. J Pharmacol Exp Ther 2011;339:99-105
   PubMed Web of Science ®Google Scholar
• Ancoli-Israel S, Vanover KE, Weiner DM, Pimavanserin tartrate, a 5-HT(2A) receptor inverse agonist, increases slow wave sleep as measured by polysomnography in healthy adult volunteers. Sleep Med 2011;12:134-41
   PubMed Web of Science ®Google Scholar
• Al-Shamma HA, Anderson C, Chuang E, Nelotanserin, a novel selective human 5-hydroxytryptamine2A inverse agonist for the treatment of insomnia. J Pharmacol Exp Ther 2010;332:281-90
   PubMed Web of Science ®Google Scholar
• Abrams JK, Johnson PL, Hay-Schmidt A, Serotonergic systems associated with arousal and vigilance behaviors following administration of anxiogenic drugs. Neuroscience 2005;133:983-97
   PubMed Web of Science ®Google Scholar
• Da Settimo F, Taliani S, Trincavelli ML, GABA A/Bz receptor subtypes as targets for selective drugs. Curr Med Chem 2007;14:2680-701
   PubMed Web of Science ®Google Scholar
• Scammell TE, Winrow CJ. Orexin receptors: pharmacology and therapeutic opportunities. Annu Rev Pharmacol Toxicol 2011;51:243-66
   PubMed Web of Science ®Google Scholar
• Coleman PJ, Renger JJ. Orexin receptor antagonists: a review of promising compounds patented since 2006. Expert Opinion Ther Patents 2010;20:307-24
   PubMed Web of Science ®Google Scholar
• Cai JQ, Cooke FE, Sherborne BS. Antagonists of the orexin receptors. Expert Opinion Ther Patents 2006;16:631-46
   Web of Science ®Google Scholar
• Roecker AJ, Coleman PJ. Orexin receptor antagonists: medicinal chemistry and therapeutic potential. Curr Top Med Chem 2008;8:977-87
   PubMed Web of Science ®Google Scholar
• Boss C, Brisbare-Roch C, Jenck F. Biomedical application of Orexin/Hypocretin receptor ligands in neuroscience. J Med Chem 2009;52:891-903
   PubMed Web of Science ®Google Scholar
• Herring WJB, Budd KS, Hutzelmann J, Efficacy and tolerability of the dual orexin receptor antagonist MK-4305 in patients with primary insomnia: randomized, controlled, adaptive crossover polysomnography study. Presented at SLEEP 2010, 24th Assoc. Prof. Sleep Soc.; 5 – 9 June; San Antonio, Texas; 2010
   Google Scholar
• Dingemanse JD, Dorffner G, Hajak G, Proof-of-concept study in primary insomnia patients with almorexant (ACT-078573), a dual orexin receptor antagonist. Presented at WorldSleep 07, 5th International Congress of the World Federation of Sleep Research and Sleep Medicine Societies; 2 – 6 September; Cairns, Austria; 2007
   Google Scholar
• Di Fabio RG, Gerrard P, Porter R, Bis-amido piperidine derivatives as in vitro and in vivo potent dual orexin receptor antagonists. Presented at 238th ACS Natl. Meeting; 16 – 20 August; Washington, D.C; 2009
   Google Scholar
• Bettica P, Nucci G, Pyke C, Phase I studies on the safety, tolerability, pharmacokinetics and pharmacodynamics of SB-649868, a novel dual orexin receptor antagonist. J Psychopharmacol 2011. [Epub ahead of print]
   Web of Science ®Google Scholar
• Ratti E. Psychiatry: an innovative drug discovery pipeline. Available from: http://www.gsk.com/investors/presentations/2007/neurosciences-seminar-dec07/emiliangelo-ratti.pdf 2007
   Google Scholar
• Coleman PC, Cox C, Breslin M, Discovery of MK-4305: a novel orexin receptor antagonist for the treatment of insomnia. Presented at 239th ACS National Meeting; 21 – 25 March; San Francisco, CA; 2010
   Google Scholar
• Various studies on GW679769 (NCT00650871, NCT00280423, NCT00280436, NCT00354809). Available from: www.clinicaltrials.gov [Last accessed January 2012] 2012
   Google Scholar
• A study with GW597599 and GR205171: potential new drugs for the treatment of insomnia (NCT00606697). Available from: www.clinicaltrials.gov [Last accessed January 2012] 2012
   Google Scholar
• Richardson GS, Roehrs TA, Rosenthal L. Tolerance to daytime sedative effects of H1 antihistamines. J Clin Psychopharmacol 2002;22:5
   Web of Science ®Google Scholar
• Balter MB, Uhlenhuth EH. New epidemiologic findings about insomnia and its treatment. J Clin Psychiatry 1992;53(Suppl):34-39; discussion 40-32
   PubMedGoogle Scholar
• Bonnet MH, Arand DL. Heart rate variability in insomniacs and matched normal sleepers. Psychosom Med 1998;60:610-15
   PubMed Web of Science ®Google Scholar